BioLight's CellDetect test gets CE Mark clearance in Europe Jun 30 2015, 11:42 ET | About: BioLight Israeli Life ... (BLGTY) | By: Douglas W. House, SA News Editor Contact this editor with comments or a news tip BioLight Life Sciences Investments (OTCQX:BLGTY) announces CE Mark clearance for its CellDetect non-invasive test for detecting bladder cancer cells in urine. The CellDirect technology is being developed by BioLight's subsidiary Micromedic Technologies.
The regulatory application process will commence in the U.S. in H1 2016.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.